Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | EEF2K | O00418 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008742 | 0.77 | LMNA (0.40) | KCNA5ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL5505984 | 0.74 | SIGMAR1 (0.49) | TSHR | |
| SCHEMBL353673 | 0.74 | EPHX2 (0.44) | KCNA5ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL353339 | 0.74 | EPHX2 (0.44) | KCNA5ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL6009865 | 0.73 | KCNA5 (0.42) | KCNA5ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL6143595 | 0.71 | LMNA (0.42) | KCNA5ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL6728558 | 0.70 | CCR5 (0.50) | ALDH1A1LMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL5146431 | 0.69 | SRC (0.44) | ALDH1A1LMNAKDM4EHPGDTSHR | |
| SCHEMBL27725242 | 0.69 | LMNA (0.50) | KCNA5ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL18329135 | 0.69 | MEN1 (0.47) | KCNA5ALDH1A1LMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | KCNA5 2873/4885ALDH1A1 1915/4885LMNA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.